GlassScriptPhysician profile
Brandy S Robbins
NPI 1609183599
$1,941.52
in general payments reported to CMS, 2019-2025
32 companies · $517 in 2025
The $517 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.93 · 2022: $655 · 2023: $495 · 2024: $254 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $30.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.61 |
| Education | $30.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $577.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $136.09 | 2022-2024 | Keytruda, Lynparza |
| Abbvie INC. | $127.11 | 2022-2025 | |
| Janssen Biotech, INC. | $94.70 | 2022-2025 | Akeega, Balversa, Erleada |
| Novocure INC. | $93.14 | 2025 | Optune Lua (Novottf-200t) |
| Incyte Corporation | $82.24 | 2022-2025 | Monjuvi |
| Lilly USA, LLC | $74.26 | 2022-2023 | Retevmo, Verzenio, Jaypirca |
| Dendreon Pharmaceuticals LLC | $61.24 | 2022-2023 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.15 | 2022-2023 | Gilotrif |
| Eisai INC. | $55.06 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.25 | 2022 | |
| Boston Scientific Corporation | $46.86 | 2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Gilead Sciences, INC. | $46.84 | 2025 | Trodelvy |
| Apellis Pharmaceuticals, INC. | $45.65 | 2023 | Empaveli |
| Sobi, INC | $43.59 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $42.58 | 2023 | Orserdu |
| Tersera Therapeutics LLC | $30.76 | 2023 | Xermelo |
| Seagen INC. | $27.44 | 2022-2023 | Tukysa |
| Genzyme Corporation | $25.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.28 | 2022 | |
| Teleflex LLC | $22.76 | 2025 | Barrigel |
| Alnylam Pharmaceuticals INC. | $20.83 | 2022 | |
| Myovant Sciences INC. | $19.93 | 2021 | |
| Olympus America INC. | $19.43 | 2025 | Connecting Tube, Single-Use Flexible Video Bronchoscope |
| Blue Earth Diagnostics | $16.89 | 2022 | |
| Puma Biotechnology, INC. | $16.51 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.43 | 2023 | Ultomiris |
| G1 Therapeutics, INC. | $15.42 | 2023 | Cosela |
| Beigene USA, INC. | $13.91 | 2022 | |
| Pfizer INC. | $13.62 | 2025 | |
| Genentech USA, INC. | $13.03 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.